Walleye Trading’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.01M | Buy |
55,100
+4,700
| +9% | +$248K | ﹤0.01% | 1605 |
|
|
2026
Q1 | $2.4M | Sell |
50,400
-20,200
| -29% | -$1.07M | ﹤0.01% | 1600 |
|
|
2025
Q4 | $3.7M | Sell |
70,600
-27,000
| -28% | -$1.62M | 0.01% | 1475 |
|
|
2025
Q3 | $6.33M | Sell |
97,600
-51,500
| -35% | -$2.96M | 0.01% | 1133 |
|
|
2025
Q2 | $7.25M | Buy |
149,100
+77,800
| +109% | +$3.01M | 0.01% | 983 |
|
|
2025
Q1 | $2.43M | Sell |
71,300
-23,000
| -24% | -$975K | 0.01% | 1519 |
|
|
2024
Q4 | $3.71M | Buy |
94,300
+65,300
| +225% | +$3.08M | 0.01% | 1340 |
|
|
2024
Q3 | $1.36M | Sell |
29,000
-1,400
| -5% | -$71K | ﹤0.01% | 1923 |
|
|
2024
Q2 | $1.64M | Sell |
30,400
-23,200
| -43% | -$1.34M | ﹤0.01% | 1725 |
|
|
2024
Q1 | $3.65M | Sell |
53,600
-58,800
| -52% | -$4.21M | 0.01% | 1338 |
|
|
2023
Q4 | $7.04M | Sell |
112,400
-3,700
| -3% | -$205K | 0.02% | 1015 |
|
|
2023
Q3 | $5.27M | Sell |
116,100
-33,800
| -23% | -$1.75M | 0.01% | 1083 |
|
|
2023
Q2 | $8.42M | Sell |
149,900
-58,500
| -28% | -$3.32M | 0.03% | 658 |
|
|
2023
Q1 | $9.43M | Sell |
208,400
-114,500
| -35% | -$5.56M | 0.02% | 655 |
|
|
2022
Q4 | $13.1M | Buy |
322,900
+24,000
| +8% | +$1.27M | 0.04% | 524 |
|
|
2022
Q3 | $19.5M | Buy |
298,900
+131,000
| +78% | +$9.49M | 0.06% | 343 |
|
|
2022
Q2 | $10.2M | Buy |
167,900
+26,700
| +19% | +$1.57M | 0.03% | 591 |
|
|
2022
Q1 | $8.86M | Buy |
141,200
+92,500
| +190% | +$5.81M | 0.03% | 690 |
|
|
2021
Q4 | $3.69M | Sell |
48,700
-13,400
| -22% | -$1.17M | 0.01% | 1169 |
|
|
2021
Q3 | $6.95M | Buy |
62,100
+9,200
| +17% | +$1.16M | 0.02% | 744 |
|
|
2021
Q2 | $8.56M | Sell |
52,900
-2,400
| -4% | -$292K | 0.03% | 508 |
|
|
2021
Q1 | $6.74M | Buy |
55,300
+41,000
| +287% | +$6.19M | 0.03% | 499 |
|
|
2020
Q4 | $2.19M | Buy |
14,300
+2,400
| +20% | +$284K | 0.01% | 1325 |
|
|
2020
Q3 | $995K | Buy |
11,900
+300
| +3% | +$26.6K | 0.01% | 1649 |
|
|
2020
Q2 | $852K | Sell |
11,600
-8,400
| -42% | -$491K | 0.01% | 1807 |
|
|
2020
Q1 | $848K | Sell |
20,000
-25,900
| -56% | -$1.34M | 0.01% | 1427 |
|
|
2019
Q4 | $2.8M | Buy |
45,900
+31,000
| +208% | +$1.69M | 0.02% | 961 |
|
|
2019
Q3 | $611K | Sell |
14,900
-27,200
| -65% | -$1.3M | 0.01% | 1968 |
|
|
2019
Q2 | $1.98M | Buy |
42,100
+36,300
| +626% | +$1.45M | 0.02% | 1052 |
|
|
2019
Q1 | $207K | Sell |
5,800
-20,100
| -78% | -$695K | ﹤0.01% | 2997 |
|
|
2018
Q4 | $740K | Buy |
25,900
+22,900
| +763% | +$796K | 0.01% | 2050 |
|
|
2018
Q3 | $133K | Buy |
+3,000
| New | +$157K | ﹤0.01% | 4043 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Walleye Trading's CRSP Position: Q2 2026 in Review
Walleye Trading increased its CRISPR Therapeutics (CRSP) stake by 23% in Q2 2026, buying an estimated $185K and bringing the position to 18,595 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2288.
Walleye Trading first reported a position in CRSP in Q4 2018 and has held it in 13 quarters since. The position peaked at $1.7M in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Walleye Trading held 18,595 shares of CRISPR Therapeutics worth $1.01M as of Q2 2026.
- Walleye Trading bought 3,509 CRISPR Therapeutics shares in Q2 2026, an estimated $185K.
- CRISPR Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #2288 holding.
- Walleye Trading first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 13 quarters since.
- Walleye Trading's CRISPR Therapeutics position peaked at $1.7M in Q2 2021.
- 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.